Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
Pfizer logo
PfizerPFE
$1.61B-0.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$688K+14.7%
OS Therapies logo
OS TherapiesOSTX
$124.94K+17,877%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's D&A?
WHWK (WHWK) reported D&A of $1K in Q1 2026.
How has WHWK's D&A changed year-over-year?
WHWK's D&A decreased by 98.2% year-over-year, from $57K to $1K.
What is the long-term trend for WHWK's D&A?
Over 3 years (2021 to 2025), WHWK's D&A has grown at a -9.1% compound annual growth rate (CAGR), from $105K to $78.9K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.